comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 22:30:15 - browse：98959

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Roche's accidental data boosts hopes for anti

entertainment

WSS

Heat waves linked to early deliveries, preterm births in new study

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

AI used to predict Covid

Latest bird flu infection made farmworker sicker than earlier cases

How the drug

hotspot

comprehensive

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Roche's accidental data boosts hopes for anti

Dobbs anniversary: the lost opportunity of abortion as health care

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

National associations that represent hospice owe an apology

Anesthesiologist group: stop taking Ozempic before surgery

Prosthetic arm enables patients to feel the objects they grip

entertainment

Dark money group runs ads on China biotech bill

California store owner shot dead in dispute over displaying Pride flag: Police

Health officials lay out plans to cope with respiratory virus season

Wegovy improves function in certain heart failure patients

As obesity drug market grows, telehealth companies court payers

David Sabatini, ex

focus

leisure time

entertainment

Wikipedia